generic synjardy availability see also generic synjardy xrsynjardy is a brand name of empagliflozinmetformin approved by the fda in the following formulation s synjardy empagliflozin metformin hydrochloride  tabletoralmanufacturer boehringer ingelheim approval date august 26 2015 strength s 5mg1gm  rld 5mg500mg  rld 125mg1gm  rld 125mg500mg  rldhas a generic version of synjardy been approved no there is currently no therapeutically equivalent version of synjardy available in the united states note fraudulent online pharmacies may attempt to sell an illegal generic version of synjardy these medications may be counterfeit and potentially unsafe if you purchase medications online be sure you are buying from a reputable and valid online pharmacy ask your health care provider for advice if you are unsure about the online purchase of any medication see also generic drug faqs related patents patents are granted by the u s patent and trademark office at any time during a drugs development and may include a wide range of claims glucopyranosylsubstituted phenyl derivatives medicaments containing such compounds their use and process for their manufacture patent 7579449 issued august 25 2009 inventor s eckhardt matthias  eickelmann peter  himmelsbach frank  barsoumian edward leon  thomas leo assignee s boehringer ingelheim international gmb h glucopyranosylsubstituted benzene derivatives of general formula i where the groups r1 to r6 as well as r7a r7b r7c are defined herein and the tautomers the stereoisomers thereof the mixtures thereof and the salts thereof the compounds according to the invention are suitable for the treatment of metabolic disorders patent expiration dates november 5 2025✓ drug substance crystalline form of 1chloro4 βdglucopyranos1yl2 4   s tetrahydrofuran3yloxybenzylbenzene a method for its preparation and the use thereof for preparing medicaments patent 7713938 issued may 11 2010 inventor s himmelsbach frank  schmid sandra  schuehle martin  martin hansjürgen  eckhardt matthias assignee s boehringer ingelheim international gmb h the invention relates to a crystalline form of 1chloro4 βdglucopyranos1yl2 4  s tetrahydrofuran3yloxybenzylbenzene to a method for the preparation thereof as well as to the use thereof for preparing medicaments patent expiration dates april 15 2027✓ drug substance✓ drug product related exclusivities exclusivity is exclusive marketing rights granted by the fda upon approval of a drug and can run concurrently with a patent or not exclusivity is a statutory provision and is granted to an nda applicant if statutory requirements are met exclusivity expiration dates august 26 2018  new productmarch 18 2019  information added to clinical studies section of the labeling regarding initial combination therapy of empagliflozin with metforminaugust 1 2019  new chemical entitydecember 2 2019  to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular diseaseadd to my med list more about synjardy empagliflozin  metforminside effects during pregnancy dosage information drug interactions support group pricing  coupons en español3 reviews – add your own reviewrating drug class antidiabetic combinations consumer resources synjardy synjardy advanced readingother brands synjardy xrprofessional resources synjardy fdarelated treatment guides diabetes type 2glossary term definition drug patent a drug patent is assigned by the u s patent and trademark office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation the patent assigns exclusive legal right to the inventor or patent holder and may include entities such as the drug brand name trademark product dosage form ingredient formulation or manufacturing process a patent usually expires 20 years from the date of filing but can be variable based on many factors including development of new formulations of the original chemical and patent infringement litigation drug exclusivity exclusivity is the sole marketing rights granted by the fda to a manufacturer upon the approval of a drug and may run simultaneously with a patent exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant rld a reference listed drug rld is an approved drug product to which new generic versions are compared to show that they are bioequivalent a drug company seeking approval to market a generic equivalent must refer to the reference listed drug in its abbreviated new drug application anda by designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent fda hopes to avoid possible significant variations among generic drugs and their brand name counterpart